graph Evidence gap map comparisons
nivolumab based treatment
nivolumab plus SoC
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2    
Comparator:  vs Standard of Care (SoC); 
Risk of bias:  low;   some concerns;   high;  NA;